Comparison Between Low FODMAP and SSRD in IBS
Launched by REGION SKANE · Dec 30, 2021
Trial Information
Current as of June 26, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
The investigator will perform a study on 200 subjects with verified irritable bowel syndrome (IBS). Participants will be recruited from the clinic of Gastroenterology or Internal medicine as well as primary health care centers. At the start of the study, participants will complete protocols concerning Rom IV criteria (to validate that the IBS criteria are ful-filled) as well as IBS symptom rating scales irritable bowel syndrome-symptoms severity scores (IBS-SSS) and visual analog scale for irritable bowel syndrome (VAS-IBS). The Item Health Survey 1.0 (distributed by RAND), RAND-36, include...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Verified IBS according to Rom IV criteria.
- Exclusion Criteria:
- • Serious mental disease
- • Serious somatic disease
- • Abuse
- • Inability to understand the Swedish language
- • Already on a diet
About Region Skane
Region Skåne is a leading healthcare authority in Sweden, dedicated to advancing medical research and improving patient care through innovative clinical trials. Committed to fostering collaboration between researchers, healthcare professionals, and patients, Region Skåne aims to enhance the understanding of various health conditions and develop effective treatment strategies. With a focus on ethical standards and patient safety, the organization plays a pivotal role in shaping the future of healthcare in the region and beyond, ensuring that clinical trials are conducted with the highest level of scientific rigor and transparency.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Malmö, , Sweden
Patients applied
Trial Officials
Bodil Ohlsson, Professor
Principal Investigator
Department of Internal Medicine
Bodil Roth, PhD
Study Chair
Department of Internal Medicine
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials